Andrew J. Armstrong, MD, Duke Cancer Center, Durham, NC, provides an overview of the phase III VISION trial (NCT03511664) of 177Lu-PSMA-617 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have progressed on androgen receptor (AR) antagonists. 177Lu-PSMA-617 provided the most benefit in patients who had brighter PSMA PET scans in terms of response rate and progression-free survival (PFS). Patients with weaker scans also responded to treatment and 177Lu-PSMA-617 is found to be superior to an additional AR antagonist. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

свернуть